title: Live viral vaccines in transplanted patients.
abstract: Live attenuated viral vaccines (LAVV) have been used safely and with great success for decades to protect healthy patients against sometimes life-threatening diseases. The current recommendations usually contraindicate their use in immunocompromised hosts, despite an often increased risk for a severe presentation of disease. In this article, we review currently available LAVV, such as varicella-zoster, measles/mumps/rubella, influenza, polio, rotavirus, and yellow fever in patients with solid organ or haematopoietic stem cell transplantation. The current paediatric and adult experience with pre- and post-transplantation vaccination is discussed. To date, because of insufficient data, evidence-based recommendations to safely vaccinate transplant recipients are not available. Hopefully in the near future, specific recommendations will be implemented for certain LAVV in these patients.
authors.affiliation: Paediatric Infectious Diseases Unit, Division of General Paediatrics, Department of Paediatrics, University Hospitals of Geneva & University of Geneva Medical School, Switzerland.
authors.forename: Arnaud G
authors.initials: AG
authors.lastname: L'Huillier
authors.affiliation: Paediatric Infectious Diseases Unit, Division of General Paediatrics, Department of Paediatrics, University Hospitals of Geneva & University of Geneva Medical School, Switzerland.
authors.forename: Klara
authors.initials: K
authors.lastname: Posfay Barbe
mesh_terms: D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D016867:Immunocompromised Host; D016377:Organ Transplantation; D014613:Vaccines, Attenuated / Q000008:administration & dosage* / Q000009:adverse effects*; D014765:Viral Vaccines / Q000008:administration & dosage* / Q000009:adverse effects*
chemical_list: D014613:Vaccines, Attenuated; D014765:Viral Vaccines